Users Online: 607
Home Print this page Email this page
Home About us Editorial board Search Browse articles Submit article Ahead of Print Instructions Subscribe Contacts Special issues Login 
ORIGINAL ARTICLE
Year : 2022  |  Volume : 11  |  Issue : 1  |  Page : 109

Renin-Angiotensin-Aldosterone axis inhibition improves outcome of diabetic patients with chronic hypertension and COVID-19: An Iranian perspective


1 Department of Internal Medicine, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
2 Infectious Disease Department, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
3 Occupational Sleep Research Center, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
4 Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Tehran, Iran
5 Gastrointestinal and Liver Diseases Research Center; Department of Virology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran
6 School of Medicine; Students' Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran
7 Department of Virology, School of Public Health; Research Center for Clinical Virology, Tehran University of Medical Sciences, Tehran, Iran
8 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran

Correspondence Address:
Dr. Hadiseh Hosamirudsari
Department of Infectious Disease, Baharloo Hospital, Tehran University of Medical Sciences, Tehran
Iran
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/abr.abr_177_21

Rights and Permissions

Background: Safe use of drugs such as angiotensin-converting enzyme 2 (ACE2) inhibitors and angiotensin receptor blockers (ARBs) in COVID diabetic patients needs comprehensive studies. This study addressed this issue from the Iranian perspective. Materials and Methods: Admitted COVID-19 patients were divided into four groups in this historical cohort study. Group 1 included 740 non-diabetic, non-hypertensive patients. Group 2 included 132 non-hypertensive diabetic patients. Group 3 included 154 non-diabetic hypertensive patients. Group 4 included 183 diabetic patients who were under ACE inhibitors or ARBs. Death, intensive care unit (ICU) admission, and length of hospitalization were compared between the groups. Results: After considering associated factors such as age, gender, dyslipidemia, cardiovascular diseases, rheumatoid arthritis (RA), chronic kidney disease (CKD), history of surgery, and corticosteroid use, diabetic patients (group 2) were associated with increased mortality (CI 95%, OR 1.93 [1.11–3.33]). Presence of diabetes (group 2) and hypertension were associated with an increased need for ICU admission (CI 95%, OR 1.69 [1.04–2.76]; CI 95%, OR 1.71 [1.08–2.71], respectively). Group 4 patients although having a similar rate of ICU admission with group 2 and 3 patients, had significantly better ICU survival. Conclusions: The current study suggests that ACE inhibitors and ARBs are associated with decreased mortality, ICU admission, and better ICU survival in the diabetic subgroup of hypertensive patients.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed376    
    Printed10    
    Emailed0    
    PDF Downloaded61    
    Comments [Add]    

Recommend this journal